VTFN.F · Vitrolife AB (publ)

-

Please sign in to comment on VTFN.F

1 Comment

Admin

4 years, 1 month ago

Vitrolife AB (publ) is currently in a long term uptrend where the price is trading 52.6% above its 200 day moving average.

From a valuation standpoint, the stock is 98.3% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 22.8.

Vitrolife AB (publ)'s total revenue sank by 6.6% to $382M since the same quarter in the previous year.

Its net income has increased by 11.5% to $107M since the same quarter in the previous year.

Finally, its free cash flow grew by 27.9% to $164M since the same quarter in the previous year.

Based on the above factors, Vitrolife AB (publ) gets an overall score of 4/5.

Exchange	F
CurrencyCode	EUR
ISIN	SE0011205202
Industry	Medical Devices
Sector	Healthcare

Beta	1.91
Market Cap	2B
PE Ratio	42.36
Target Price	None
Dividend Yield	0.7%

ABOUT

Vitrolife AB (publ)

Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware products, such as dishes, pipettes, tubes, and VitroTemp. Vitrolife AB (publ) was incorporated in 1989 and is based in Gothenburg, Sweden.

VTFN.F · Vitrolife AB (publ)

-

Vitrolife AB (publ)

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Vitrolife AB (publ) using a moving average strategy